Blood Podcast

Епизоде

• 
  Exploiting Vulnerabilities in High‑Risk MM and Mapping the Red Cell Interactome 17.09.2026 30мин

  In this week's episode, Blood editor Dr. Laurie Sehn interviews Drs. Mariateresa Fulciniti and Angelo D'Alessandro on their latest articles published in Blood. Dr. Fulciniti, of the Dana Farber Cancer Institute, discusses the development of "PKMYT1 is a targetable vulnerability in del(17p) high-risk multiple myeloma" starting from the question, "Is 17P loss simply a prognostic marker, or does it create specific vulnerabilities that we can therapeutically exploit?" Then, Dr. D'Alessandro, of the University of Colorado, discusses "The red blood cell proteome and interactome identify a Band 3–BLVRB axis regulating hypoxic metabolic adaptation." His team began by asking, "What's in a red blood cell? How many proteins are there, and how can we confidently claim that these now several 1000s of proteins in opposite excess are indeed proteins within red blood cells are not coming from contaminants?" Both studies describe how deep molecular profiling can uncover specific, potentially targetable biological dependencies or interaction axes that may enable more precise, mechanism‑based therapeutic strategies.
• 
  MYB driven ALL and Venetoclax-Azacitidine damage to Bone Marrow 10.09.2026 24мин

  In this week's episode, Blood editor Dr. James Griffin interviews Drs. Thomas Milne and Dominique Bonnet on their latest articles published in volume 147 issue 24 of Blood. Dr. Milne discusses how transcription factors simultaneously activate enhancers and connect them to their target genes in KMT2A-rearranged acute lymphoblastic leukemia. The binding of MYB, a key hematopoietic TF, is sufficient to drive novel enhancer activation, including initiating 3D contact with target promoters to drive ectopic expression of distal oncogenes.  Continued MYB binding is required to maintain enhancer-promoter interactions, indicating that disruption of MYB is therapeutically tractable in multiple leukemias. Then, considering bone marrow vasculature, Dr. Bonnet discusses how the use of in vivo models to identify selective injury to sinusoidal endothelial cells caused by venetoclax-azacitidine, revealed a therapy-associated mechanism that links BM niche damage to impaired hematopoietic recovery. These data help explain the prolonged BM hypoplasia observed in some patients and prompt further research into how other targeted therapy-based induction regimens influence the BM microenvironment.Featured ArticlesMYB activity drives emergent enhancer activation and enhancer-promoter interactions in acute lymphoblastic leukemiaRemodeling of the bone marrow vasculature induced by venetoclax and azacitidine damage
• 
  Predictive Markers of Glofitamab Resistance in R/R B-NHL 03.09.2026 15мин

  In this week's episode, Blood editor Dr. Laurie Sehn interviews Drs. Camille Laurent and Christine Bezombes on their latest article published in Blood titled "Patient-derived lymphoma spheroids reveal predictive markers of glofitamab resistance in relapsed/refractory B-NHL." By using patient-derived lymphoma spheroids as an ex vivo platform, they identify key mechanisms of resistance to the bispecific T-cell engager glofitamab in B-cell non-Hodgkin lymphoma, showing that higher CD8 T-cell abundance and cytotoxic activity is associated with better therapeutic responses, while increased T follicular helper (Tfh) cells correlate with resistance. The authors further show that resistance could be overcome by depleting Tfh cells or combining glofitamab with TIGIT (T-cell immunoreceptor with Ig and ITIM domains) blockade, highlighting promising strategies to improve responses to T-cell engager therapies.
• 
  Better Together: Adding daratumumab for AL Amyloidosis and and Mezigdomide for MM 27.08.2026 26мин

  In this week's episode, Blood editor Laurie Sehn interviews Drs. Efstathios Kastritis and Lucia Chen on their latest articles published in Blood. Dr. Kastritis shares insights and results from the final survival analysis of the ANDROMEDA trial, which determined that adding daratumumab to cyclophosphamide, bortezomib, and dexamethasone improves hematologic responses and overall survival in newly diagnosed AL amyloidosis.  Dr. Chen elaborates on the key benefits of Ikaros degradation for reducing T-cell dysfunction in MM patients: Ikaros degradation by mezigdomide enhances anti–B-cell maturation antigen CAR-T and bispecific TCE therapy efficacy in vitro and in vivo. Featured Articles: Daratumumab-Bortezomib-Cyclophosphamide-Dexamethasone for Newly Diagnosed Amyloidosis: ANDROMEDA Final Survival Analysis | Efstathios KastritisIkaros degradation by mezigdomide reduces T-cell dysfunction and improves the efficacy of antimyeloma T-cell therapies | Lucia Chen
• 
  Balancing Infection and Thrombosis: Bispecific Antibodies and the Many Roles of HRG 20.08.2026 15мин

  In this week's episode, Blood editor Dr. Laura Michaelis interviews Drs. Joshua Hill and Jeffery Weitz on their latest articles published in Blood. Dr. Hill and Dr. Michaelis discuss the evolving landscape of infection risk in adults receiving bispecific antibody therapies for advanced B‑cell malignancies. They explore how these risks differ from those seen with allogeneic transplant, CAR T‑cell therapy, and traditional CD20‑directed antibodies, and touch on emerging approaches such as trispecific antibodies and evolving strategies for supportive care, including immunoglobulin replacement. In the second half of the episode, Dr. Michaelis is joined by Dr. Jeffrey Weitz to discuss new insights into the role of histidine‑rich glycoprotein in hemostasis. Their conversation delves into HRG’s interactions with key platelet receptors, its behavior in inflammatory states like sepsis and COVID‑19, and how these observations may reshape thinking about thrombosis risk and future therapeutic approaches.Featured Articles: How I prevent infections in adults receiving bispecific antibody therapies for advanced B-cell malignancies | Joshua Hill, MDHistidine-rich glycoprotein modulates platelet adhesion and aggregation by binding to GPIbα and GPIIb/IIIa | Jeffery Weitz, MD
• 
  Cost-Effectiveness of Current SCD Treatments and Potential Therapeutic Targets for Fetal Hemoglobinopathies 13.08.2026 32мин

  In this week's episode, Blood editor Dr. James Griffin interviews Drs. George Goshua, Gerd Blobel, and Paul Kaminski on their latest articles published in Blood. Dr. Goshua elaborates on the background and then insights from "Haploidentical transplant, gene therapy, and standard care in sickle cell disease: a cost-effectiveness analysis". This analysis provides valuable guidance for clinicians, patients, and health systems as they consider treatment choices. However, as concluded in the accompanying Blood Commentary, the true measure of success is not which therapy “wins” the economic argument, but whether each patient receives the therapy best suited to their clinical needs and values. Then, Drs. Gerd Blobel and Paul Kaminski share "Dissecting polycomb complexes for enhanced fetal hemoglobin production", which utilizes a comprehensive CRISPR-based screen to interrogate the components of these repressive complexes and identified a single protein domain in EZH2, a subunit of PRC2, as a potential therapeutic target. They demonstrate that inhibition of the domain encoded by exon 14 of EZH2 selectively derepresses fetal hemoglobin expression, raising the possibility of developing drugs that specifically target this domain to treat hemoglobinopathies.
• 
  HLH-like toxicities after CAR-T and Structure-Function Relationships of FNAIT 06.08.2026 16мин

  In this week's episode, Blood editor Dr. Laura Michaelis interviews Drs. Matthew Frank and Jieqing Zhu on their latest articles published in volume 147 issue 22 of Blood. Dr. Frank discusses "How I treat HLH-like toxicities after immune effector cell therapy", in which the two cases presented emphasize the need for early identification, the use of anticytokine therapy with either emapalumab or ruxolitinib when organ toxicities worsen despite conventional CRS-directed treatment, and the need for ancillary supportive care as central to success. Dr. Zhu shares insights from "Structural Basis of HPA-1 a Alloimmunization in FNAIT and Allosteric Regulation of Integrin Conformation" where they probed the structure-function relationships underpinning interactions of alloantibodies against the most common target, human platelet antigen 1a (HPA-1a). Their data can help explain why some alloantibodies cause severe hemorrhagic FNAIT while others result in milder, asymptomatic thrombocytopenia.
• 
  FLT3-ITD microclones in AML and Results from the RESET-PV trial 30.07.2026 13мин

  In this week's episode, Blood editor Dr. Laura Michaelis interviews Drs. Pierre-Yves Dumas and Samik Basu on their latest articles published in Blood. Dr. Dumas talks about "Prognostic impact of FLT3-ITD microclones in young adults with acute myeloid leukemia treated with intensive chemotherapy" where the team was able to identify that ultra-low-burden FLT3-ITD microclones are associated with higher relapse risk and inferior relapse-free survival. Their work encourages the evaluation of FLT3 inhibitor strategies. Dr. Basu discusses "CD19 CAR T-cell therapy is feasible for patients with pemphigus vulgaris treated without lymphodepletion in the RESET-PV trial". In four patients, the treatment was well tolerated and supported CAR T-cell expansion and persistence, challenging the need for lymphodepletion and supporting chemotherapy-free approaches in autoimmune disease.
• 
  Initial CHORUS data on HHT and ASH HematOmics Program 23.07.2026 26мин

  In this week's episode, Blood editor Dr. James Griffin interviews Drs. Hanny Al-Samkari and Xin Zhou on their latest articles published in Blood. This episode highlights two important advances in hematology: the first report from the CHORUS registry for hereditary hemorrhagic telangiectasia (HHT) presented by Dr. Al-Samkari and also the introduction of the ASH Hematomics (ASHOP) platform for integrative genomic data analysis presented by Dr. Zhou. The CHORUS registry reveals that HHT is a progressive, underrecognized inherited bleeding disorder with a substantial burden of recurrent bleeding, iron deficiency, arteriovenous malformations, and life-threatening complications, while emphasizing the need for earlier diagnosis and the development of targeted therapies. The second presentation introduces ASHOP, an open-access platform that enables researchers to explore and integrate large-scale clinical and genomic datasets, facilitating discoveries in leukemia and other hematologic diseases through advanced analytical tools. Together, these studies demonstrate how comprehensive patient registries and innovative data-sharing resources are advancing precision medicine, improving disease understanding, and accelerating future research across hematology.
• 
  IV Iron during Acute Infection and Revisiting iTTP Refractoriness 16.07.2026 16мин

  In this week's episode, Blood editor Dr. James Griffin interviews Drs. Haris Sohail and Lucas Kühne on their latest articles published in volume 147 issue 21 of Blood. In this CME article titled, "Retrospective, Real-World Study of IV Iron Use to Treat Iron deficiency Anemia During Acute Infection",  Sohail et al show that IV iron given during acute infection with iron deficiency anemia is associated with improved 14-day and 90-day survival as well as hemoglobin recovery. Although this report has the limitations of a retrospective study, these findings challenge current practice and support randomized trials that include patients with infection. In "Revisiting Clinical Response and Refractoriness in Immune Thrombotic Thrombocytopenic Purpura", Kühne et al show in a multicenter registry study of 204 patients that refractoriness during caplacizumab treatment in immune TTP is uncommon and, when observed, is typically associated with confounding clinical factors. These findings underscore the importance of careful clinical reassessment and evaluation for alternative etiologies in patients with delayed platelet recovery, rather than attributing such cases to true treatment resistance.
• 
  A Pediatric ITP Risk Model and Targeting CD2 with CAR T-cell therapies 09.07.2026 18мин

  In this week's episode, Blood editor Dr. Laura Michaelis interviews Drs. Kirsty Hillier and Marco Ruella on their latest articles published in Blood. For "Predicting Development of Pediatric Chronic Immune Thrombocytopenia at Disease Onset Using a Statistical Risk Model", Dr. Hillier shares the potential benefits of incorporating this new model to enhance the care of the 1 in 4 patients who develop chronic ITP. As an alternative to current guidelines which advise providers to "wait and see", this online model determines patients who are at risk for chronic ITP, allowing for providers to make informed decisions on their continued care. In "Harnessing the CD2 axis to broaden and enhance the efficacy of CAR T-cell therapies", Dr. Ruella explains how the treatment of T-cell neoplasms is limited by a lack of discriminating T-cell antigens that allow for effective antitumor responses while preventing CAR T-cell fratricide. The team found that CD2 was a viable target, especially combined with a novel PD-1:CD2 switch receptor to remedy dysfunction caused by CD2 deletion.  
• 
  IV Iron Risks and Low-Dose AML Gains 02.07.2026 24мин

  In this week's episode, Blood editor Dr. James Griffin interviews Drs. Heinz Zoller and Raul Ribeiro on their latest articles published in Blood. Dr. Zoller discusses "Ferric Carboxymaltose Increases Fracture Risk in Patients and Reduces Bone Formation in Mice with Iron Deficiency Anemia", and how these findings support consideration of alternative IV iron formulations that provide similar efficacy without risk of skeletal complications.  Dr. Ribeiro discusses "A low-versus standard-dose regimen an induction for AML: a multicenter, randomized noninferiority trial" and how the low-dose regimen is associated with fewer toxicities, faster hematologic recovery, and reduced health care costs, suggesting a feasible treatment strategy for resource-limited settings.
• 
  Orca-T for GVHD–free survival and Understanding VEXAS anemia 25.06.2026 23мин

  In this week's episode, Blood editor Dr. Laurie Sehn interviews Drs. Everett Meyer and Olivier Hermine on their latest articles published in volume 147 issue 11 of Blood. Dr. Everett Meyer discusses "Orca-T vs allogeneic hematopoietic stem cell transplantation (PRECISION-T): a multicenter, randomized phase 3 trial" which demonstrated that Orca-T showed superior chronic GVHD–free survival compared to the control arm (78.0% vs 38.4%, P < .001) and lower nonrelapse mortality (3.4% vs 13.2%, P = .03). Dr. Olivier Hermine shares insights from "VEXAS anemia is a mosaic erythroblastopenia" which proposes that VEXAS syndrome–associated anemia should be considered as a mosaic erythroblastopenia, in which the severity of anemia is influenced by the quality and quantity of the UBA1–wild-type compartment.
• 
  Treating AML, Before and After Relapse 18.06.2026 16мин

  In this episode, Blood editor Dr. Laura Michaelis interviews Drs. Nigel Russell and Uwe Platzbecker on their articles published in volume 147 issue 10 of Blood. Dr. Russell discuses "CPX-351 vs daunorubicin, cytarabine, and gemtuzumab ozogamicin in older adults with non–adverse-risk AML: the NCRI AML18 trial" where a large randomized trial demonstrated that DA-GO2 provided greater overall survival as compared to CPX-351, and that further studies should compare DA-GO2 to lower-intensity venetoclax-based regimens. Dr. Platzbecker shares insights from the first prospective study to evaluate the clinical impact of early therapeutic intervention for MRD in "Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trial" demonstrating potential therapies for patients to achieve and maintain remission.
• 
  Future Directions in Relapsed and Refractory Large B-cell Lymphoma 11.06.2026 25мин

  In this week's episode, Blood editor Dr. Philippe Armand interviews Drs. Manali Kamdar and Nancy L. Bartlett on their latest review article published in Blood titled “From breakthroughs to blueprints: evolving evidence and future directions in relapsed and refractory large B-cell lymphoma”. They discuss the how the advent of chimeric antigen receptor T cells, antibody-drug conjugates, and bispecific antibodies all show major increases in efficacy over legacy chemotherapy-based regimens. They also share their insights on how to transform treatment paradigms in light of these breakthroughs.
• 
  Review Series on Clonal Tracking in Hematopoiesis 04.06.2026 30мин

  In this Review series episode, Blood associate editor Dr. Diane Krause interviews contributing authors from the Review Series on Clonal tracking in Hematopoiesis published in volume 147 issue 23 of Blood. Dr. Alejo E. Rodriguez-Fraticelli speaks to the development of his paper, "Clonal tracing of blood stem cells across mouse and human lifespans”, which provides a detailed overview of the experimental approaches that make clonal analysis possible, and which approaches are most appropriate to use to address specific questions. Dr. Shalin H. Naik speaks about how different clonal tracking approaches have been used to address the central question of clonal fate specification of stem and progenitor cells to specific lineages in “The evolution of hematopoietic models through a clonal lens”. Finally, Dr. Federico Gaiti speaks about “Methylation-based lineage tracing in cancer”, which takes these ideas into the context of cancer, focusing on how DNA methylation can be used to reconstruct clonal relationships.  
• 
  New Approaches: Marstacimab Therapy and HLH Biomarkers 28.05.2026 17мин

  In this week's episode, Blood editor Dr. James Griffin interviews Drs. Johnny Mahlangu and Joseph Rocco on their articles published in volume 147 issue 9 of Blood.  Dr. Mahlangu discusses study details and next steps from "Efficacy and safety of marstacimab prophylaxis in hemophilia A/B with inhibitors: results from the phase 3 BASIS trial" which shows that bleeding was reduced by 93% with subcutaneous marstacimab. Dr. Rocco shares the development behind "CXCL9 as a novel prognostic marker to identify high-risk adults with hemophagocytic lymphohistiocytosis", and the insights gained from measuring a new surrogate marker of IFN-γ activity predicting severity and mortality.
• 
  Review Series on Hemophagocytic Lymphohistiocytosis (HLH) 21.05.2026 16мин

   In this episode, Blood deputy editor Dr. Helen Heslop interviews contributing  authors from the Blood review series on hemophagocytic lymphohistiocytosis. Drs. Nancy Berliner and Joanne Hsu join to provide insight on their paper, “Hemophagocytic lymphohistiocytosis in adults” discussing the importance of prompt diagnosis and treatment in this high-mortality disorder, and highlight emerging agents designed to modulate disease progression. Drs. Carl Allen and Bethany Verkamp reimagine diagnostic criteria through a threshold model in “Pediatric hemophagocytic lyphohistiocytosis: current conceptualization, diagnosis, and treatment”, in order to provide individualized therapies with the goal of addressing the combined influence of genetic susceptibility and environmental triggers.
• 
  IBD augmentation of CHIP and Platelet mTOR's impact on Cerebral Malaria 14.05.2026 20мин

  In this week's episode, Blood editor Dr. Laurie Sehn interviews Drs. Reuben Kapur and Robert Campbell on their latest articles published in Blood. This episode highlights two groundbreaking studies exploring how inflammation drives serious blood and immune-related diseases. In the first interview, Dr. Kapur discusses how inflammatory bowel disease (IBD) can both promote and worsen clonal hematopoiesis of indeterminate potential (CHIP), with large-scale human data and mouse models identifying REF1 as a key mediator and potential therapeutic target. The second segment features Dr. Campbell, who explains how heme released during malaria infection activates platelet mTOR signaling, intensifying cerebral malaria and suggesting new avenues for platelet-targeted treatments. Together, the conversations reveal how inflammatory pathways and immune signaling contribute to disease progression while opening the door to novel precision therapies. 
• 
  Long-term efficacy and safety of betibeglogene autotemcel for β-thalassemia 07.05.2026 13мин

  In this week's episode, Blood editor Dr. Laura Michaelis interviews Dr. Alexis Thompson, former ASH president, on her latest article published in Blood. Dr. Thompson discusses "Long-term efficacy and safety results of betibeglogene autotemcel gene therapy for transfusion-dependent β-thalassemia." She explains transfusion-dependent β-thalassemia (TDT) requires rigorous, lifelong transfusion therapy and iron chelation to manage iron overload. Dr. Kwiatkowski and colleagues discuss the long-term efficacy and safety of this gene therapy in 63 patients with TDT, documenting sustained transfusion independence for up to 10 years and a safety profile consistent with that of myeloablative autologous transplantation.